An Integrated Approach for Screening and Identification of Positive Allosteric Modulators of N-Methyl-D-Aspartate Receptors

N-methyl-D-aspartate receptors (NMDARs) are ionotropic glutamate receptors that play an important role in synaptic plasticity and learning and memory formation. Malfunctioning of NMDARs, in particular the reduction in NMDAR activity, is thought to be implicated in major neurological disorders. NMDAR positive allosteric modulators (PAMs) represent potential therapeutic interventions for restoring normal NMDAR function. We report a novel screening approach for identification and characterization of NMDAR-PAMs. The approach combines high-throughput fluorescence imaging with automated electrophysiological recording of glutamate-evoked responses in HEK-293 cells expressing NR1/NR2A NMDAR subunits. Initial high-throughput screening (HTS) of a chemical library containing >810,000 compounds using a calcium flux assay in 1536-well plate format identified a total of 864 NMDAR-PAMs. Concentration response determination in both calcium flux and automated electrophysiological assays found several novel chemical series with EC50 values between 0.49 and 10 µM. A small subset (six series) was selected and analyzed for pharmacological properties, subtype selectivity, mode of action, and activity at native NMDARs. Our approach demonstrates the successful application of HTS functional assays that led to identification of NMDAR-PAMs providing the foundation for further medicinal chemistry work that may lead to novel therapies for treatment of cognitive impairment associated with Alzheimer’s disease and schizophrenia.

[1]  P. Ornstein,et al.  6-substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists. , 1992, Journal of medicinal chemistry.

[2]  S. Paul,et al.  Steroid potentiation and inhibition of N-methyl-D-aspartate receptor-mediated intracellular Ca++ responses: structure-activity studies. , 1994, The Journal of pharmacology and experimental therapeutics.

[3]  M. Bennett,et al.  Spermine potentiation of recombinant N-methyl-D-aspartate receptors is affected by subunit composition. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Purdy,et al.  Distinct sites for inverse modulation of N-methyl-D-aspartate receptors by sulfated steroids. , 1997, Molecular pharmacology.

[5]  Tamara Hershey,et al.  Ketamine-Induced NMDA Receptor Hypofunction as a Model of Memory Impairment and Psychosis , 1999, Neuropsychopharmacology.

[6]  L. Martin,et al.  N-Methyl-d-aspartate receptor subunit proteins and their phosphorylation status are altered selectively in Alzheimer’s disease , 2001, Journal of the Neurological Sciences.

[7]  F. Mora,et al.  Glutamatergic neurotransmission in aging: a critical perspective , 2001, Mechanisms of Ageing and Development.

[8]  D. Goff,et al.  Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia , 2003, Annals of the New York Academy of Sciences.

[9]  P. Dodd,et al.  Differential expression of N‐methyl‐d‐aspartate receptor NR2 isoforms in Alzheimer's disease , 2004, Journal of neurochemistry.

[10]  R. Astur,et al.  Selective Cognitive Impairments Associated with NMDA Receptor Blockade in Humans , 2005, Neuropsychopharmacology.

[11]  P. Paoletti,et al.  NMDA receptor subunits: function and pharmacology. , 2007, Current opinion in pharmacology.

[12]  H. Ropers,et al.  Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes , 2010, Nature Genetics.

[13]  D. Liotta,et al.  A subunit-selective potentiator of NR2C- and NR2D-containing NMDA receptors. , 2010, Nature Communications.

[14]  D. Skifter,et al.  A Novel Family of Negative and Positive Allosteric Modulators of NMDA Receptors , 2010, Journal of Pharmacology and Experimental Therapeutics.

[15]  Laetitia Mony,et al.  Identification of a novel NR2B-selective NMDA receptor antagonist using a virtual screening approach. , 2010, Bioorganic & medicinal chemistry letters.

[16]  D. Liotta,et al.  Quinazolin-4-one derivatives: A novel class of noncompetitive NR2C/D subunit-selective N-methyl-D-aspartate receptor antagonists. , 2010, Journal of medicinal chemistry.

[17]  J. Snyder,et al.  Implementation of a Fluorescence-Based Screening Assay Identifies Histamine H3 Receptor Antagonists Clobenpropit and Iodophenpropit as Subunit-Selective N-Methyl-d-Aspartate Receptor Antagonists , 2010, Journal of Pharmacology and Experimental Therapeutics.

[18]  A. Capelli,et al.  Identification and Characterization of Novel NMDA Receptor Antagonists Selective for NR2A- over NR2B-Containing Receptors , 2010, Journal of Pharmacology and Experimental Therapeutics.

[19]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[20]  G. Collingridge,et al.  Piperazine-2,3-dicarboxylic acid derivatives as dual antagonists of NMDA and GluK1-containing kainate receptors. , 2012, Journal of medicinal chemistry.

[21]  Anne de Saint Martin,et al.  GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction , 2013, Nature Genetics.

[22]  David Lodge,et al.  The NMDA receptor as a target for cognitive enhancement , 2013, Neuropharmacology.

[23]  Gabriel M. Belfort,et al.  The Major Brain Cholesterol Metabolite 24(S)-Hydroxycholesterol Is a Potent Allosteric Modulator of N-Methyl-d-Aspartate Receptors , 2013, The Journal of Neuroscience.

[24]  J. Snyder,et al.  Structural Determinants and Mechanism of Action of a Glun2c- Selective Nmda Receptor Positive Allosteric Modulator Running Title: Analysis of a Glun2c Nmdar Positive Allosteric Modulator , 2022 .

[25]  E. Banks,et al.  De novo mutations in schizophrenia implicate synaptic networks , 2014, Nature.